Pharmacogenetic study in metastatic colorectal cancer (CRC) patients receiving third-line panitumumab-irinotecan: A GERCOR ancillary study.
Marie-Christine Etienne-Grimaldi
No relevant relationships to disclose
Laurence Llorca
No relevant relationships to disclose
Patricia Formento
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Christophe Tournigand
Honoraria - Amgen
May Mabro
No relevant relationships to disclose
Jean-Baptiste Bachet
No relevant relationships to disclose
Helene Blons
No relevant relationships to disclose
Pierre Laurent-Puig
Consultant or Advisory Role - Amgen
Jean-Louis Formento
No relevant relationships to disclose
Aimery De Gramont
Consultant or Advisory Role - Amgen
Thierry Andre
Consultant or Advisory Role - Amgen
Honoraria - Merck Serono; Roche
Gerard A. Milano
No relevant relationships to disclose